# Effectiveness of Escitalopram in Preventing or Reducing Depressive Symptoms in People Receiving Interleukin-2 Treatment

> **NCT00352885** · PHASE4 · COMPLETED · sponsor: **Emory University** · enrollment: 20 (actual)

## Conditions studied

- Depression

## Interventions

- **DRUG:** Escitalopram
- **DRUG:** Placebo
- **DRUG:** IL-2

## Key facts

- **NCT ID:** NCT00352885
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10-06
- **Primary completion:** 2010-05-17
- **Final completion:** 2010-05-17
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2018-09-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00352885

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00352885, "Effectiveness of Escitalopram in Preventing or Reducing Depressive Symptoms in People Receiving Interleukin-2 Treatment". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT00352885. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*